%0 Journal Article %A Ayesha Jameel %A Wladyslaw Gedroyc %A Dipankar Nandi %A Bryn Jones %A Olga Kirmi %A Sophie Molloy %A Yen Tai %A Gavin Charlesworth %A Peter Bain %T Two year data from a preliminary study of double lesion site MRgFUS treatment of Essential Tremor targeting the thalamus and the posterior subthalamic area %D 2021 %R 10.1101/2020.12.27.20248723 %J medRxiv %P 2020.12.27.20248723 %X Background MR-guided focused ultrasound (MRgFUS) is an effective treatment for essential tremor (ET). However, the optimal intracranial target sites remain to be determined.Objective To assess MRgFUS induced sequential lesions in (anterior-VIM/VOP nuclei) the thalamus and then posterior subthalamic area (PSA) performed during the same procedure for alleviating ET.Methods 14 patients had unilateral MRgFUS lesions placed in anterior-VIM/VOP then PSA. Bain-Findley Spirals were collected during MRgFUS from the treated arm (BFS-TA) and throughout the study from the treated (BFS-TA) and non-treated (BFS-NTA) arms and scored by blinded assessors. Although, the primary outcome was change in the BFS-TA from baseline to 12 months we have highlighted the 24 month data.Secondary outcomes included the Clinical Rating Scale for Tremor (CRST), Quality of Life for ET (QUEST) and PHQ-9 depression scores.Results The mean improvement in the BFS-TA from baseline to 24 months was 41.1% (p<0.001) whilst BFS-NTA worsened by 8.8% (p<0.001). Intra-operative BFS scores from the targeted arm showed a mean 27.9% (p<0.001) decrease after anterior-VIM/VOP ablation and an additional 30.1% (p<0.001) reduction from post anterior-VIM/VOP to post-PSA ablation.Mean improvements at 24 month follow-up in the CRST-parts A, B and C were 60.7%, 30.4% and 65.6% respectively and 37.8% in QUEST-tremor score (all p<0.05). Unilateral tremor severity scores decreased in the treated arm (UETTS-TA) 72.9% (p=0.001) and non-treated arm (UETTS-NTA) 30.5% (p=0.003). At 24 months residual adverse effects were slight unsteadiness (n=1) and mild hemi-chorea (n=1).Conclusion Unilateral anterior-VIM/VOP and PSA MRgFUS significantly diminished contralateral arm tremor with improvements in arm function, tremor related disability and quality of life, with an acceptable adverse event profile.Competing Interest Statement1. The study was funded by InsighTec the manufacturer of the Neuro-ablate device. 2. Dr Bain is a trustee to the National Tremor Foundation (UK Charity)Clinical TrialNCT01827904Funding Statement1. The study was funded by InsighTec the manufacturer of the Exablate Neuro system. 2. The institution received a 1.2 million BPS donation from the Imperial College Healthcare Charity to purchase the InsighTec Exablate Neuro system.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:1. London Riverside Research Ethics Committee, Level 3 Block B. Whitefriars, Lewins Mead, Bristol, BS1 2NT United Kingdom (REC no: 15LO1538) - APPROVED 2. Imperial College Healthcare NHS Trust Trust The Bays South Wharf Road St Mary's Hospital London W2 1NY United Kingdom (ID: 155M2876) - APPROVEDAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data up to 2 years post MRgFUS is available on request. %U https://www.medrxiv.org/content/medrxiv/early/2021/01/02/2020.12.27.20248723.full.pdf